Johnson & Johnson (JNJ)vsSolid Biosciences LLC (SLDB)
JNJ
Johnson & Johnson
$262.38
+0.78%
HEALTHCARE · Cap: $632.29B
SLDB
Solid Biosciences LLC
$9.10
-1.09%
HEALTHCARE · Cap: $972.00M
Smart Verdict
WallStSmart Research — data-driven comparison
JNJ leads profitability with a 21.5% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
SLDB
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-87.7%
Fair Value
$139.75
Current Price
$262.38
$122.63 premium
Intrinsic value data unavailable for SLDB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Earnings declined 0.9%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : SLDB
The strongest argument for SLDB centers on Debt/Equity, Price/Book.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : SLDB
The primary concerns for SLDB are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
JNJ profiles as a mature stock while SLDB is a value play — different risk/reward profiles.
SLDB carries more volatility with a beta of 2.42 — expect wider price swings.
JNJ is growing revenue faster at 6.6% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 31/100), backed by strong 21.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Solid Biosciences LLC
HEALTHCARE · BIOTECHNOLOGY · USA
Solid Biosciences Inc., a life sciences company, is dedicated to developing therapies for Duchenne muscular dystrophy (DMD) in the United States. The company is headquartered in Cambridge, Massachusetts.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?